Last edition
News about Global Pharma
Clearmind Biomedical Signs US Distribution Agreement with Sutter Medical Technologies USA
Clearmind Biomedical has partnered with Sutter Medical to exclusively distribute its 510(k)-cleared Neuroblade Neuro-Endoscope System in the US, advancing treatment for intracerebral hemorrhage—one of the most severe and hard-to-treat stroke types.
Global Pharma | 06/10/2025 | By Dineshwori | 257
Hikma, Celltrion Deepen Ties to Boost Biosimilar Access in Middle East and North Africa
British multinational pharmaceutical company Hikma Pharmaceuticals has signed new exclusive licensing agreements with its long-standing partner, South Korea’s Celltrion, covering the Middle East and North Africa (MENA) region.
Global Pharma | 06/10/2025 | By Dineshwori | 357
Avobis Bio’s lead therapeutic, AVB-114, has received FDA’s RMAT designation for Crohn’s perianal fistulas, building on its Fast Track status to accelerate development with enhanced regulatory support and guidance.
Global Pharma | 06/10/2025 | By Dineshwori | 298
FDA Flags Lupin's Pithampur Manufacturing Facility with Official Action Indicated Status
Lupin stated that it is actively engaging with the U.S. regulator and remains committed to maintaining full compliance with current Good Manufacturing Practice (cGMP) standards across all its manufacturing sites.
Global Pharma | 06/10/2025 | By Darshana | 531
Lupin Launches Liraglutide Injection in US
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use pre-filled pen is bioequivalent to Victoza injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc.
Global Pharma | 04/10/2025 | By Dineshwori | 224
Titan Pharmaceuticals Completes Merger with Black Titan and TalenTec
Titan Pharmaceuticals has completed its merger with Black Titan Corporation, a Cayman Islands exempted company, and TalenTec, a Malaysian private limited company. The transaction closed successfully on October 1, 2025, making Titan a wholly owned subsidiary of Black Titan.
Global Pharma | 04/10/2025 | By Dineshwori | 729
Daiichi Sankyo Establishes Third Research Institute in San Diego
Daiichi Sankyo Research Institutes, located in Boston, Munich and San Diego, are advancing the vision of Daiichi Sankyo to foster the development of next-generation medicines.
Global Pharma | 04/10/2025 | By Dineshwori | 155
India's USD 12 Billion MedTech Sector Set to Surge to USD 50 billion by 2030: Dr Jitendra Singh
Union Minister Dr. Jitendra Singh noted that institutions like SCTIMST, with recognition from WHO and collaborations with national agencies such as ICMR, DBT, CSIR, DRDO and INSA, can contribute to India’s emergence as a global hub for cost-effective healthcare and medical tourism by 2047.
Global Pharma | 04/10/2025 | By Dineshwori | 199
Celltrion Launches Tocilizumab Biosimilar AVTOZMA IV in the US Market
AVTOZMA is Celltrion's fifth immunology biologic and seventh biosimilar approved by the US FDA. It will be available in the same presentations as its reference product, Actemra (tocilizumab).
Global Pharma | 03/10/2025 | By Dineshwori | 469
Lupin Launches Generic Xarelto Rivaroxaban Oral Suspension in US
Global pharma major Lupin has announced the launch of Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States.
Global Pharma | 03/10/2025 | By Dineshwori | 405
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy